General Statement of Disclosure:

CONSULTING FEES/HONORARIA: United Therapeutics(SIGNIFICANT), Keros(MODEST), Acceleron/Merck(SIGNIFICANT), Medtronic(NONE), Aerovate(MODEST), Jucabio(NONE) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Intellia- former employee end July 2024(SIGNIFICANT) RESEARCH/RESEARCH GRANTS: Aerovate(SIGNIFICANT), Gossamer(SIGNIFICANT), Keros(SIGNIFICANT) SALARY: Pathos(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Janssen Pharmaceuticals, Inc (Actelion)(MODEST)

View Full Disclosure